Article
Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Aug 2015
Drilon Alexander, Wang Lu, Arcila Maria E, Balasubramanian Sohail, Greenbowe Joel R, Ross Jeffrey S, Stephens Phil, Lipson Doron, Miller Vincent A, Kris Mark G, Ladanyi Marc, Rizvi Naiyer A
Abstract excerpt
PURPOSE: Broad, hybrid capture-based next-generation sequencing (NGS), as a clinical test, uses less tissue to identify more clinically relevant genomic alterations compared with profiling with multiple non-NGS tests. We set out to determine the frequency of such genomic alterations via this approach in tumors in which previous extensive non-NGS testing had not yielded a targetable driver alteration. EXPERIMENTAL...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.